Trinity Biotech Announces CE Marking of New Meritas Heart

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Trinity Biotech Announces CE Marking of New Meritas Heart Failure (BNP) Point-of-Care Test

DUBLIN, Sept. 25, 2014 (GLOBE NEWSWIRE) -- Trinity Biotech plc. (Nasdaq: TRIB ), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced it has obtained the CE mark (i.e. European approval) for its Meritas point-of-care BNP test.

Heart failure, also referred to as chronic or congestive heart failure, is a complex progressive syndrome that impacts about 26 million people worldwide with almost 700,000 new cases diagnosed each year in the United States alone. Heart failure is a serious condition in which the heart cannot pump enough blood to meet the needs of the body. Although often life threatening, the typical symptoms of heart failure (breathlessness, fatigue and swelling of the limbs) are usually less dramatic than those associated with a heart attack. In economically developed countries, up to one in five people are expected to develop heart failure at some point in their life. As the symptoms of heart failure are variable and non-specific, blood-based biomarkers are frequently used to assist in the difficult diagnosis of heart failure.

Brain or B-type natriuretic peptide (BNP) levels in the bloodstream increase as the severity of heart disease proceeds. Thus, BNP has emerged as the principal biomarker in aiding the diagnosis of and determining the clinical severity of acute and chronic heart failure. In addition, BNP can be useful in a wide range of clinical applications including risk stratification and monitoring of patients with heart failure and heart attacks.

The Meritas BNP test demonstrates exceptional sensitivity and precision, which is at least comparable to much larger and far more expensive central laboratory systems, while delivering results in ten minutes, right at the point-of-care. Existing competitive BNP tests have certain limitations due to the effects of sample degradation. This makes those tests challenging to use in primary care and in retrospective studies, where sample degradation may falsely lower test results. Due to its design the new patented Meritas BNP test is not hindered by these limitations.

The worldwide point-of-care BNP market is estimated to be approximately $300m p.a. with a growth rate of 12% p.a. With this European approval, we are now in a position to immediately enter the BNP market with a product that is at least as good as, if not better than, the current market leaders. However, of greater significance from a commercial perspective is that it will run side by side, on the same platform as Trinity's Troponin product for the detection of heart attacks. This test already demonstrates significantly superior performance to any point-of-care test currently on the Troponin market, which itself is worth $350m p.a. at the point-of-care. Consequently, by having the highest quality combined product offering, Trinity is uniquely positioned to successfully target and achieve a significant share of the combined BNP and Troponin point-of-care market of $650m.

Following the receipt of CE Marking, we will immediately commence our marketing efforts in Europe, whilst at the same time preparing for FDA submission. Given that most of the CE Mark data was already generated in the USA, it will now be augmented with additional USA trial data, with a view to submitting to the FDA by the end of quarter 1, 2015. BNP approval is anticipated during quarter 3, 2015 which is expected to coincide with FDA approval of our Troponin product, thus giving us the vital menu components for a product launch in the US, where the bulk of the cardiac point-of-care market resides.

Commenting on today's news, Ronan O'Caoimh, CEO of Trinity Biotech, said "We are pleased to expand the Meritas family of products, improve patient outcomes and resolve longstanding testing challenges. Trinity's best in class technology affords us many development possibilities. Our outstanding new Meritas BNP test is our second step into the point-of-care cardiac testing market following on from the launch of our Troponin test for detecting heart attacks. Collectively our Troponin and BNP tests will target point-of-care markets which are estimated to be US$650m annually. In addition, and particularly in the case of Troponin, we will also be targeting the laboratory based markets for these products which have value of a further $900m.

We are now committed to quickly expanding the Meritas menu further with the addition of a series of high value tests at the point-of-care. The next test is a D-dimer test for deep vein thrombosis, development of which is well underway and will further complement our testing panel".

Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com .

Trinity Biotech plc Kevin Tansley (353)-1-2769800 E-mail: Lytham Partners LLC Joe Diaz, Joe Dorame & Robert Blum 602-889-9700

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 138

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 84

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 89

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 100

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 162

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 49

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 195

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 103

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 104

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading

Top 5 Most Recently Viewed Articles

Why Investors Are Making Bold Moves with Dell Technologies

Updated Category News Views 178

Investors Show Confidence in Dell Technologies In recent trading sessions, significant investors have adopted a bullish approach to Dell Technologies (NYSE: DELL). Such movements usually signal investor confidence and the possibility of future price movements. Interestingly, options trading data we've analyzed indicates that this activity stemmed from large transactions,...

Continue Reading
Community Heritage Financial Strengthens Capital Position with Debt Offering

Updated Category News Views 78

Community Heritage Financial Completes Subordinated Debt Offering Community Heritage Financial, Inc. (OTC PK: CMHF), parent company of Middletown Valley Bank, has successfully executed a private placement of subordinated debt, amounting to a substantial $12.1 million. This offering of 6.75% Fixed-to-Floating Rate Subordinated Notes, due 2034, reflects the Company’s...

Continue Reading
Evolent Health Poised for Growth Amid Humana Challenges

Updated Category News Views 185

Understanding Evolent Health's Market Position Recently, analysts at Barclays have reaffirmed their positive outlook on Evolent Health (NYSE: EVH), maintaining an Overweight rating and a price target of $39.00. This confidence comes in light of discussions surrounding the impacts of Humana's recent struggles with Medicare Star ratings. The management team at Evolent,...

Continue Reading
Caracole Teams with Centric PLM for Seamless Growth

Updated Category News Views 31

Revolutionizing the Luxury Furniture Game In the world of luxury furnishings, where every curve and finish sends a message, Caracole is making a bold move to streamline its operations. They're throwing the confetti for Centric PLM, a platform that's set to oust the scattered chaos of spreadsheets and emails. And let me tell you, for any investor eyeing the luxury home...

Continue Reading
RaySearch Laboratories: Exciting Year-End Presentation Ahead

Updated Category News Views 105

Join Us for RaySearch Laboratories' Year-End Report Presentation Analysts, investors, and media representatives are cordially invited to a detailed presentation focused on RaySearch Laboratories' Year-end report for the year 2024. Details of the Presentation Set for February 21, 2025, at 10:00 AM CET, the report will be made accessible to attendees starting at 07:45 AM on...

Continue Reading